- Home
- IONS vs JHG Comparison
IONS vs JHG Comparison
Compare IONS & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- JHG
- Stock Information
- Founded
- IONS 1989
- JHG 1934
- Country
- IONS United States
- JHG United Kingdom
- Employees
- IONS N/A
- JHG N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- JHG Investment Managers
- Sector
- IONS Health Care
- JHG Finance
- Exchange
- IONS Nasdaq
- JHG Nasdaq
- Market Cap
- IONS 4.6B
- JHG 4.7B
- IPO Year
- IONS 1991
- JHG N/A
- Fundamental
- Price
- IONS $32.26
- JHG $36.36
- Analyst Decision
- IONS Buy
- JHG Buy
- Analyst Count
- IONS 18
- JHG 11
- Target Price
- IONS $57.41
- JHG $41.27
- AVG Volume (30 Days)
- IONS 1.7M
- JHG 1.5M
- Earning Date
- IONS 04-30-2025
- JHG 05-01-2025
- Dividend Yield
- IONS N/A
- JHG 4.42%
- EPS Growth
- IONS N/A
- JHG N/A
- EPS
- IONS N/A
- JHG 2.52
- Revenue
- IONS $717,253,000.00
- JHG $2,542,900,000.00
- Revenue This Year
- IONS N/A
- JHG $2.34
- Revenue Next Year
- IONS $27.39
- JHG $6.01
- P/E Ratio
- IONS N/A
- JHG $14.40
- Revenue Growth
- IONS N/A
- JHG 17.85
- 52 Week Low
- IONS $23.95
- JHG $28.26
- 52 Week High
- IONS $52.34
- JHG $46.68
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- JHG 61.16
- Support Level
- IONS $31.66
- JHG $34.54
- Resistance Level
- IONS $33.98
- JHG $37.05
- Average True Range (ATR)
- IONS 1.30
- JHG 0.98
- MACD
- IONS 0.41
- JHG 0.66
- Stochastic Oscillator
- IONS 68.84
- JHG 90.23
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.